Posted inNews and Updates
CAR T-Cell Therapy Shows Promise for Rare Amyloidosis
A groundbreaking clinical trial reveals CAR T-cell therapy shows promise for treating AL amyloidosis by targeting the root cause of protein buildup.
Posted inNews and Updates
Thykamine™ Clinical Trial Approved for Pediatric Eczema
Health Canada has approved a Phase II/III clinical trial for Thykamine™ to treat pediatric atopic dermatitis in patients aged 3 months to 17 years.
Posted inNews and Updates
JAK Inhibitors for Vitiligo: Clinical Updates & Safety Data
Explore the latest clinical data on systemic JAK inhibitors for vitiligo. Discover how this emerging treatment works, its efficacy, and vital safety protocols.
Posted inNews and Updates
Eli Lilly’s $2.8 Billion Venture Into Psychedelic Research
Eli Lilly invests $2.8 billion to pioneer psychedelic research, aiming to overcome the limitations of traditional clinical trial infrastructure.
Posted inNews and Updates
iPSC Cell Therapy Shows Promise for Spinal Cord Injuries
New Phase 1 trial data reveals the safety and potential of iPSC-derived cell therapy to treat subacute spinal cord injuries and promote neural recovery.
Posted inNews and Updates
Phanes Therapeutics Expands Spevatamig Combo Trial for BTC
Phanes Therapeutics expands its clinical trial with Merck to test Spevatamig alongside KEYTRUDA and chemotherapy for treating biliary tract cancer.
Posted inNews and Updates
Pharmability Receives Approval for Atopic Dermatitis Phase Ib Trial
Pharmability gains Swedish MPA approval for a Phase Ib trial of TIR-C, a promising new therapeutic candidate for treating chronic atopic dermatitis.
Posted inNews and Updates
Bulumtatug Fuvedotin Shows Promise in Pretreated TNBC
Mabwell’s bulumtatug fuvedotin shows clinical potential for triple-negative breast cancer patients previously treated with topoisomerase I inhibitors.
Posted inNews and Updates
4D-150 Shows Long-Term Efficacy in Treating Wet AMD
New 2-year data confirms 4D-150 gene therapy provides sustained vision improvements for wet AMD patients, potentially reducing the need for recurring injections.
Posted inNews and Updates
OMEICOS Advances OMT-28 to Phase 3 for Mitochondrial Disease
OMEICOS has initiated a Phase 3 trial for OMT-28, a potential breakthrough treatment targeting mitochondrial disease. Learn about this new clinical milestone.